Research Indicates Potential Connection Between Prenatal Medication

Key Points:

• A University of Nebraska Medical Center study analyzing over six million maternal-child health records found that prenatal exposure to sterol biosynthesis-inhibiting medications (SBIMs), including common antidepressants, antipsychotics, beta-blockers, and statins, is associated with a 1.47-fold increased risk of autism spectrum disorder (ASD) in children.
• The risk of ASD rises with the number of SBIMs prescribed during pregnancy, reaching a 2.33-fold increase when four or more such medications are co-administered, with prenatal SBIM exposure rising from 4.3% in 2014 to 16.8% in 2023.
• The study highlights that disruption of cholesterol biosynthesis—a critical pathway for fetal brain development—may underlie this increased autism risk, drawing parallels to genetic disorders like Smith-Lemli-Opitz syndrome that affect the same pathway and are linked to ASD.
• Researchers urge caution in prescribing these medications during pregnancy, advocating for enhanced clinical vigilance, further research on biochemical impacts, and development of safer therapeutic strategies to balance maternal health needs with fetal neurodevelopmental safety.
• The findings call for multidisciplinary efforts, including integrating sterol metabolism assessments into drug development, educating clinicians on neurodevelopmental risks, and tailoring treatments based on genetic susceptibilities to reduce ASD risk associated with prenatal medication exposure.